Kindred Biosciences Company Profile (NASDAQ:KIN)

About Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences logoKindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KIN
  • CUSIP: N/A
  • Web:
  • Market Cap: $232.45 million
  • Outstanding Shares: 27,837,000
Average Prices:
  • 50 Day Moving Avg: $7.64
  • 200 Day Moving Avg: $7.39
  • 52 Week Range: $3.90 - $9.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.32
  • P/E Growth: -0.16
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.07 per share
  • Price / Book: 2.65
  • EBITDA: ($24,990,000.00)
  • Return on Equity: -37.00%
  • Return on Assets: -35.40%
  • Current Ratio: 29.87%
  • Quick Ratio: 29.87%
  • Average Volume: 116,706 shs.
  • Beta: 0.19
  • Short Ratio: 2.39

Frequently Asked Questions for Kindred Biosciences (NASDAQ:KIN)

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. View Kindred Biosciences' Earnings History.

When will Kindred Biosciences make its next earnings announcement?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Kindred Biosciences.

Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?

5 equities research analysts have issued 12 month price objectives for Kindred Biosciences' shares. Their forecasts range from $7.50 to $10.50. On average, they expect Kindred Biosciences' share price to reach $9.00 in the next year. View Analyst Ratings for Kindred Biosciences.

Who are some of Kindred Biosciences' key competitors?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:

  • Wendy Wee, Chief Financial Officer
  • Denise M. Bevers, Chief Operating Officer, Secretary
  • Stephen Sundlof Ph.D., Executive Vice President - Regulatory Affairs and Quality, Chief Scientific Officer
  • Herbert D. Montgomery, Independent Director
  • Raymond Townsend, Independent Director
  • Ervin Veszpremi, Independent Director

How do I buy Kindred Biosciences stock?

Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of Kindred Biosciences stock can currently be purchased for approximately $8.15.

MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Kindred Biosciences (NASDAQ:KIN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (10.43% upside)
Consensus Price Target History for Kindred Biosciences (NASDAQ:KIN)
Price Target History for Kindred Biosciences (NASDAQ:KIN)
Analysts' Ratings History for Kindred Biosciences (NASDAQ:KIN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017AegisInitiated CoverageBuy$10.50HighView Rating Details
5/31/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/15/2017BMO Capital MarketsReiterated RatingHold$8.00N/AView Rating Details
1/3/2017Feltl & Co.Reiterated RatingStrong-BuyN/AView Rating Details
11/1/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$7.50N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Kindred Biosciences (NASDAQ:KIN)
Earnings by Quarter for Kindred Biosciences (NASDAQ:KIN)
Earnings History by Quarter for Kindred Biosciences (NASDAQ KIN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.33)N/AView Earnings Details
8/7/2017Q2 2017($0.33)($0.29)ViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.30)ViewListenView Earnings Details
3/1/2017Q416($0.36)($0.29)ViewListenView Earnings Details
11/7/2016Q316($0.36)($0.29)ViewListenView Earnings Details
8/8/2016Q216($0.32)($0.25)ViewN/AView Earnings Details
3/2/2016Q415($0.44)($0.32)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.44)($0.36)ViewN/AView Earnings Details
8/10/2015Q2($0.42)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.40)($0.34)ViewN/AView Earnings Details
3/12/2015Q414($0.40)($0.34)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.43)($0.31)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.35)($0.42)ViewN/AView Earnings Details
5/12/2014Q1 14($0.18)($0.38)ViewN/AView Earnings Details
3/6/2014($0.21)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Kindred Biosciences (NASDAQ:KIN)
Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS


Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Kindred Biosciences (NASDAQ:KIN)
Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 60.37%
Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)
Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)
Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/12/2017Park West Asset Management LlcMajor ShareholderBuy600,000$7.50$4,500,000.00View SEC Filing  
7/3/2017Richard ChinInsiderSell13,000$8.26$107,380.00View SEC Filing  
6/22/2017Richard ChinInsiderSell13,000$7.75$100,750.00View SEC Filing  
6/8/2017Park West Asset Management LlcMajor ShareholderBuy15,311$6.65$101,818.15View SEC Filing  
5/11/2017Park West Asset Management LlcMajor ShareholderBuy155,076$6.83$1,059,169.08View SEC Filing  
3/15/2017Park West Asset Management LlcMajor ShareholderBuy400,000$6.60$2,640,000.00View SEC Filing  
3/13/2017Park West Asset Management LlcMajor ShareholderBuy4,200$6.20$26,040.00View SEC Filing  
3/9/2017Park West Asset Management LlcMajor ShareholderBuy18,066$6.08$109,841.28View SEC Filing  
1/13/2017Park West Asset Management LlcMajor ShareholderBuy1,690,000$6.20$10,478,000.00View SEC Filing  
1/9/2017Park West Asset Management LlcMajor ShareholderBuy131,500$5.30$696,950.00View SEC Filing  
1/6/2017Park West Asset Management LlcMajor ShareholderBuy110,617$5.10$564,146.70View SEC Filing  
12/16/2016Park West Asset Management LlcInsiderSell18,000$4.78$86,040.00View SEC Filing  
12/14/2016Park West Asset Management LlcMajor ShareholderBuy8,334$4.75$39,586.50View SEC Filing  
12/13/2016Park West Asset Management LlcMajor ShareholderBuy1,148$4.75$5,453.00View SEC Filing  
12/12/2016Park West Asset Management LlcMajor ShareholderBuy3,112$4.74$14,750.88View SEC Filing  
3/15/2016Ernest MarioDirectorBuy30,000$3.55$106,500.00View SEC Filing  
11/23/2015Raymond TownsendDirectorBuy2,000$4.00$8,000.00View SEC Filing  
11/18/2015Raymond TownsendDirectorBuy2,323$4.78$11,103.94View SEC Filing  
8/31/2015Raymond TownsendDirectorBuy1,677$5.85$9,810.45View SEC Filing  
8/14/2015Raymond TownsendDirectorBuy3,000$6.04$18,120.00View SEC Filing  
9/29/2014Oleg NodelmanDirectorBuy100,000$9.56$956,000.00View SEC Filing  
9/3/2014Ernest MarioDirectorBuy10,000$10.55$105,500.00View SEC Filing  
8/28/2014Oleg NodelmanDirectorBuy47,000$10.85$509,950.00View SEC Filing  
8/26/2014Oleg NodelmanDirectorBuy85,244$10.50$895,062.00View SEC Filing  
12/12/2013Kevin SchultzInsiderBuy4,000$7.00$28,000.00View SEC Filing  
12/12/2013Oleg NodelmanDirectorBuy400,000$7.00$2,800,000.00View SEC Filing  
12/12/2013Stephen SundlofSVPBuy1,000$7.00$7,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Kindred Biosciences (NASDAQ:KIN)
Latest Headlines for Kindred Biosciences (NASDAQ:KIN)
DateHeadline logoKindred Biosciences to Announce Third Quarter 2017 Financial Results - October 11 at 5:05 PM logoContrasting Kindred Biosciences (KIN) & Pain Therapeutics (PTIE) - October 6 at 4:10 PM logoKindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference - October 6 at 2:37 AM logoHead-To-Head Analysis: Spark Therapeutics (ONCE) & Kindred Biosciences (KIN) - October 1 at 2:32 AM logoKindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Analysts - September 27 at 8:44 PM logoKindred Biosciences (KIN) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow - September 27 at 4:17 PM logoComparing Kindred Biosciences (KIN) and Its Peers - September 20 at 8:08 AM logoKindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof - September 11 at 9:35 PM logoKindred Biosciences, Inc. (KIN) Given Average Rating of "Buy" by Analysts - September 2 at 8:46 PM logoKindred Biosciences to Present at Upcoming Investor Conferences - August 31 at 6:40 AM logoKindred Biosciences, Inc. (KIN) Short Interest Down 29.0% in July - August 14 at 3:04 AM logoKindred Biosciences, Inc. (NASDAQ:KIN) Releases Quarterly Earnings Results - August 8 at 11:14 AM logoEdited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT - August 8 at 5:40 AM logoKindred Biosciences Announces Second Quarter 2017 Financial Results - August 7 at 7:38 PM logoKindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting - August 4 at 11:59 PM logo Brokerages Anticipate Kindred Biosciences, Inc. (KIN) Will Post Earnings of -$0.29 Per Share - August 2 at 10:14 PM logoKindred Biosciences, Inc. (KIN) Short Interest Update - July 29 at 7:15 AM logoBRIEF-Kindred Biosciences says board appointed Wendy Wee as CFO - SEC Filing - July 29 at 1:09 AM logoKindred Biosciences to Announce Second Quarter 2017 Financial Results - July 24 at 10:19 AM logoKindred Biosciences, Inc. (NASDAQ:KIN) Receives Average Rating of "Buy" from Brokerages - July 14 at 10:52 PM logoPark West Asset Management Llc Purchases 600,000 Shares of Kindred Biosciences, Inc. (KIN) Stock - July 14 at 7:59 PM logoKindredBio Announces Pricing of Public Offering - July 13 at 6:07 AM logoBRIEF-Kindredbio announces proposed public offering of common stock - July 12 at 1:51 AM logoKindredBio Announces Proposed Public Offering of Common Stock - July 12 at 1:51 AM logoKindred Biosciences, Inc. (NASDAQ:KIN) Expected to Post Earnings of -$0.29 Per Share - July 11 at 2:28 PM logoFormer Boehringer Ingelheim manufacturing plant finds new owner - July 7 at 6:46 AM logoRichard Chin Sells 13,000 Shares of Kindred Biosciences, Inc. (KIN) Stock - July 6 at 8:06 PM logoKindred Biosciences (KIN) Buys Kansas Manufacturing Plant and Reports Execution of Commercial Manufacturing Agreement for Zimeta - June 26 at 8:03 PM logoBRIEF-Kindred Biosciences reports acquisition of Kansas manufacturing plant - June 26 at 8:03 PM logoBRIEF-Kindred Biosciences announces Q1 loss per share $0.30 - May 4 at 1:16 AM logoKindred Biosciences, Inc. 2017 Q1 - Results - Earnings Call Slides - May 4 at 1:16 AM logoQ4 2016 Kindred Biosciences Inc Earnings Release - After Market Close - March 1 at 11:27 AM logoKindred Biosciences (KIN) Receives Technical Section Complete Letter for Effectiveness from FDA for Mirataz New Animal Drug Application - February 6 at 11:19 PM logoBRIEF-Kindred Biosciences receives early approval of effectiveness technical section from FDA for Mirataz - February 6 at 6:17 PM logo9:00 am Kindred Biosciences receives early approval of effectiveness technical section from the FDA for Mirataz new animal drug application (shares halted) - February 6 at 10:21 AM logoKindred Biosciences (KIN) Looks Good: Stock Jumps 9.5% - January 16 at 8:35 AM logoKindredBio: An Undervalued, Under-Followed, Low-Float Play On The Humanization Of Pets - January 14 at 12:26 AM logoKINDRED BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement - December 20 at 11:45 AM logoKINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - December 7 at 6:14 PM logoBRIEF-Kindred Biosciences to present Zimeta pivotal data at Annual American Association of Equine Practitioners Convention - November 29 at 4:18 PM logoTracking Seth Klarman's Baupost Group Holdings - Q3 2016 Update - November 16 at 9:29 AM logoKindred Biosciences Announces Third Quarter 2016 Financial Results - November 7 at 9:38 AM logoKindred Biosciences (KIN) Submits Safety Technical Section to FDA Related to Mirataz NADA - September 30 at 10:58 AM logoKindred Biosciences (KIN) Submits Mirataz's New Animal Drug Application Technical Section to FDA - August 23 at 10:14 AM logoKindred Biosciences Submits New Animal Drug Application Technical Section for Effectiveness for Mirataz to FDA - August 23 at 10:14 AM logoQ2 2016 Kindred Biosciences Inc Earnings Release - After Market Close - August 8 at 10:32 AM



Kindred Biosciences (KIN) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.